The reduction in price target by Truist Securities suggests that they see less upside potential for Coherus BioSciences, which could lead to a negative short-term impact on the stock price. However, the maintenance of a Buy rating indicates a positive outlook on the company's fundamentals, which may mitigate some of the negative impact.